🇺🇸 FDA
Patent

US 12421512

CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

granted A61KA61K48/00

Quick answer

US patent 12421512 (CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K48/00